Northwest Biotherapeutics, (id:11182 NWBO)
0.270 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 9:24:59 PM)
Exchange closed, opens in 12 hours 4 minutes
-5.26 USD (-5.26%)
-8.47 USD (-8.47%)
-10.00 USD (-10.00%)
-38.64 USD (-38.64%)
-63.51 USD (-63.51%)
22.73 USD (22.73%)
-95.05 USD (-95.05%)
-96.25 USD (-96.25%)
About Northwest Biotherapeutics,
Market Capitalization 393.07M
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
| Headquarters (address) |
4800 Montgomery Lane Bethesda 20814 MD United States |
| Phone | 240 497 9024 |
| Website | https://www.nwbio.com |
| Employees | 25 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | NWBO |
| Exchange | OTC Markets U.S. |
| Currency | USD |
| 52 week range | 0.240 - 0.880 |
| Market Capitalization | 393.07M |
| P/E trailing | -4.50 |
| Price/Sale | 238.95 |
| Price/Book | -4.29 |
| Beta | -0.556 |
| EPS | -0.070 |
| EPS United States (ID:6, base:3402) | 24.23 |